Drug Trial Radar · NCT07746479
A Study to Evaluate the Efficacy and Safety of LZM012 ( Psoriasis )
Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
244
Actual
Start
Jun 23, 2025
Primary completion
Jan 26, 2026
Study completion Jan 26, 2026
Sponsor
- Lead sponsor
- Livzon Pharmaceutical Group Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Multicenter, Open-Label, Single-Arm Phase III Clinical Trial to Evaluate the Efficacy and Safety of LZM012 Injection in Patients With Moderate to Severe Plaque Psoriasis.
Conditions
- Psoriasis
Interventions
LZM012Biological
Recombinant anti-human IL-17A/F humanized monoclonal antibody injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- PASI100 response rateTime frame: At week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Dermatology Hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.